Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 1/20 | 0.36 |
| ▸ | GSTA1 | P08263 | 5/20 | 0.34 |
| ▸ | GSTP1 | P09211 | 5/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | PTPRC | P08575 | 4/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.31 |
| ▸ | PTPRB | P23467 | 4/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | CRHBP | P24387 | 2/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20121198 | 0.96 | CD69 (0.34) | CD69GSTA1GSTP1CYP2D6TSHR | |
| SCHEMBL20121194 | 0.94 | SMN1; SMN2 (0.42) | CD69MTNR1ALMNACRHBPCRHR2 | |
| SCHEMBL20121197 | 0.90 | SMN1; SMN2 (0.40) | MTNR1ALMNACRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL14093080 | 0.88 | CD69 (0.34) | CD69SMN1; SMN2 | |
| SCHEMBL18505802 | 0.87 | CD69 (0.36) | CD69GSTA1GSTP1CYP2D6TSHR | |
| SCHEMBL2626909 | 0.81 | GSTA1 (0.43) | GSTA1GSTP1MTNR1ALMNACRHBP | |
| SCHEMBL2626904 | 0.81 | GSTA1 (0.43) | GSTA1GSTP1MTNR1ALMNACRHBP | |
| SCHEMBL2626907 | 0.81 | GSTA1 (0.43) | GSTA1GSTP1MTNR1ALMNACRHBP | |
| SCHEMBL20445405 | 0.81 | — | — | |
| SCHEMBL13129398 | 0.76 | CD69 (0.69) | CD69TSHRPTPN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215882-A1 | SWELLABLE AND INSOLUBLE NANOFIBERS AND USE THEREOF IN THE TREATMENT OF ESSENTIALLY AQUEOUS EFFLUENTS | AJELIS (FR) | 2018-08-02 | — | — | US | disclosed |
| US-9966157-B2 | Solid-liquid process for extraction of radionuclides from waste solutions | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2018-05-08 | — | — | US | disclosed |
| US-20170044142-A1 | NOVEL COMPLEXES FOR THE SEPARATION OF CATIONS | UNIVERSITE PARIS-SUD (FR) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044142-A1 | NOVEL COMPLEXES FOR THE SEPARATION OF CATIONS | PICALM, SOD1, MATR3 | CD69 3498/4885GSTA1 4472/4885GSTP1 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.